Leinco Technologies

Anti-Clozapine - (Clone CLO-4718)

Product Code:
 
LEI-C548
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
Mouse IgG1 κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
CLO-4718
Regulatory Status:
 
RUO
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Lateral-Flow Immunochromatographic Assay
Shipping:
 
2 - 8°C Wet Ice
Storage:
 
This purified antibody is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C548-1.0mg1.0 mg£707.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Show All

Further Information

Concentration:
≥1.0 mg/ml
Formulation:
Formulated in 0.015M potassium phosphate buffered saline (0.85%), pH 7.2 and contains 0.05% sodium azide.
Product Description:
Clozapine, a unique atypical antipsychotic, is primarily employed in the treatment of schizophrenia, particularly in cases resistant to other antipsychotic medications. Introduced in the 1970s, clozapine stands out due to its distinct mechanism of action, primarily antagonizing dopamine receptors, but also influencing other neurotransmitter systems, including serotonin, histamine, and adrenergic receptors. This broad-spectrum modulation contributes to its efficacy in managing symptoms. Notably, clozapine is associated with a risk of agranulocytosis, a potentially life-threatening reduction in white blood cell count. Due to this risk, regular blood monitoring, specifically complete blood cell counts, is crucial for individuals on clozapine therapy. These diagnostic tests are essential for detecting early signs of agranulocytosis, allowing for prompt intervention and ensuring the overall safety and effectiveness of clozapine treatment in patients with severe or treatment-resistant schizophrenia.
Target:
Clozapine